Email Alert | RSS

北京大学学报（医学版） ›› 2020, Vol. 52 ›› Issue (5): 971-974. doi: 10.19723/j.issn.1671-167X.2020.05.030

• 病例报告 • 上一篇    下一篇

同时性多原发肺腺癌组织编码转录因子ERG基因相同位点突变1例报告

鲍轶1,2,∆(),莫娟芬2   

  1. 1.浙江省嘉兴市第二医院 肿瘤科,浙江嘉兴 314000
    2.浙江省嘉兴市第二医院 中心实验室,浙江嘉兴 314000
  • 收稿日期:2018-10-16 出版日期:2020-10-18 发布日期:2020-10-15
  • 通讯作者: 鲍轶 E-mail:ybao2011@gmail.com
  • 基金资助:
    嘉兴市科技计划(2016AY23054);浙江省医药卫生科技计划(2016KYB292)

Concordant point mutation of ETS-related gene (ERG) in tumor tissues from a synchronous multiple primary lung cancer: A case report

Yi BAO1,2,∆(),Juan-fen MO2   

  1. 1. Department of Oncology, The Second Hospital of Jiaxing, Jiaxing 314000, Zhejiang, China
    2. Key Laboratory, The Second Hospital of Jiaxing, Jiaxing 314000, Zhejiang, China
  • Received:2018-10-16 Online:2020-10-18 Published:2020-10-15
  • Contact: Yi BAO E-mail:ybao2011@gmail.com
  • Supported by:
    Science and Technology Bureau of Jiaxing(2016AY23054);Health Bureau of Zhejiang Province(2016KYB292)

RICH HTML

   

PDF (PC)

摘要：

关键词: 肺肿瘤, 肿瘤, 多原发性, ETS相关基因, 突变, 高通量核苷酸序列分析

Abstract:

The rearrangement of the gene encoding the transcription factor ETS-related gene (ERG) is thought to play a key role in the development of prostate cancer. However, the studies on the ERG mutations have been rarely reported in non-small cell lung carcinoma (NSCLC). Here, we reported genetic features regarding a case of a 68-year-old male patient who presented the primary synchronous multiple tumor lesions in the separated lungs. The patient was hospitalized due to the presence of tumor lesions at the right and left lungs revealed by a chest computerized tomography (CT) scan. After conducting lobectomies at the both lungs, the tumor nodules were all removed, and the histological analysis suggested adenocarcinoma at the both tumor lesions. The patient was diagnosed with synchronous multiple primary lung cancer (SMPLC) based on Martini-Melamed criteria and American College of Chest Physicians practice guidelines. An exome analysis of 315 genes in the two tumor lesions and a non-tumor lesion was conducted by using Illumina Nextseq500 platform from each tumor region to decipher a potential evolutional progress of SMPLC. Single or pair-end reads were first mapped to a human genome reference and filtered based on the mapping quality score. The read depth was ≥ 1 000× and the depth of coverage was 95%. The data revealed a discordant epidermal growth factor receptor (EGFR) from the separate lungs; additionally, a high frequency of point mutation on exon 9 H310P of the ERG gene was detected at the both sites of the tumor lesions. This case showed that a potential role of the molecular features analysis from each tumor lesion might contribute to the understanding of the evolutional development of SMPLC. This study suggests that the same environment may contribute certain gene(s) mutations in the same sites in the early stages of polyclonal tumor origins; meanwhile the extensive studies on these genes may help us understand the evolution and progress of tumor clones.

Key words: Lung neoplasms, Neoplasms, multiple primary, ETS-related gene, Mutation, High-throughput nucleotide sequencing

中图分类号: 

  • R734.2

图1

术前胸部CT扫描图像"

表1

315个基因组合中突变频率≥5%的体细胞突变在两侧癌灶间的对比"

Items Tumor nodule Gene Chromosome location Gene mutation Density Mutation frequency
Discordant (≥5%) Left side EGFR 7p11.2 exon21,c.2573T>G,p.L858R 1 844 15%(290/1 884)
ACVR1B 12q13.13 exon2,c.106T>A,p.C36S 554 9%(48/554)
GRIN2A 16p13.2 exon11,c.2326G>A,p.D776N 647 9% (56/647)
ATR 3q23 exon47,c.7912C>T,p.L2638F 483 7% (32/483)
EGFR 7p11.2 exon19,c.2240T>C,p.L747S 2 906 7% (207/2 906)
CBFR 16q22.1 exon5,c.481C>T,p.R161W 951 5% (48/951)
NF1 17q11.2 exon33,c.4462C>T,p.R1488C 775 5% (35/775)
NOTCH2 1p12 exon34,c.7153A>C,p.T2385P 914 5% (44/914)
Right side ARID2 12q12 exon5,c.539G>A,p.C180Y 588 6%(34/588)
ARID2 12q12 exon15,c.1960C>G,p.P654A 1 058 5% (48/1 058)
Concordant(≥5%) Left side ERG 21q22.2 exon9,c.929A>C,p.H310P 637 9% (60/637)
Right side ERG 21q22.2 exon9,c.929A>C,p.H310P 929 8% (74/929)

图2

利用cBioportal数据分析平台研究TCGA非小细胞肺癌ERG突变情况"

图3

通过cBioportal数据分析平台研究TCGA非小细胞肺癌ERG突变与总生存率的关系"

[1] Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer[J]. Nat Rev Cancer, 2008,8(7):497-511.
doi: 10.1038/nrc2402 pmid: 18563191
[2] Brenner JC, Ateeq B, Li Y, et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer[J]. Cancer Cell, 2011,19(5):664-678.
doi: 10.1016/j.ccr.2011.04.010
[3] Wang X, Qiao Y, Asangani IA, et al. Development of peptidomimetic inhibitors of the ERG gene gusion product in prostate cancer[J]. Cancer Cell, 2017,31(4):532-548.
doi: 10.1016/j.ccell.2017.02.017 pmid: 28344039
[4] Martini N, Melamed MR. Multiple primary lung cancers[J]. J Thorac Cardiovasc Surg, 1975,70(4):606-612.
pmid: 170482
[5] Kozower BD, Larner JM, Detterbeck FC. Special treatment issues in non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines[J]. Chest, 2013,143(5 Suppl):e369S-e399S.
doi: 10.1378/chest.12-2362 pmid: 23649447
[6] Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin[J]. Cancer, 1953,6(5):963-968.
doi: 10.1002/1097-0142(195309)6:5<963::aid-cncr2820060515>3.0.co;2-q pmid: 13094644
[7] Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma[J]. Nature, 2014,511(7511):543-550.
doi: 10.1038/nature13385
[8] Jamal-Hanjani M, Wilson GA, McGranahan N, et al. Tracking the evolution of non-small-cell lung cancer[J]. N Engl J Med, 2017,376(22):2109-2121.
doi: 10.1056/NEJMoa1616288 pmid: 28445112
[9] Adamo P, Ladomery MR. The oncogene ERG: A key factor in prostate cancer[J]. Oncogene, 2016,35(4):403-414.
doi: 10.1038/onc.2015.109 pmid: 25915839
[10] Ida K, Kobayashi S, Taki T, et al. EWS-FLI-1 and EWS-ERG chimeric mRNAs in Ewing’s sarcoma and primitive neuroectodermal tumor[J]. Int J Cancer, 1995,63(4):500-504.
doi: 10.1002/ijc.2910630407 pmid: 7591257
[11] Nagai N, Ohguchi H, Nakaki R, et al. Downregulation of ERG and FLI1 expression in endothelial cells triggers endothelial-to-mesenchymal transition[J]. PLoS Genet, 2018,14(11):e1007826.
doi: 10.1371/journal.pgen.1007826 pmid: 30500808
[1] 李志存, 吴天俣, 梁磊, 范宇, 孟一森, 张骞. 穿刺活检单针阳性前列腺癌术后病理升级的危险因素分析及列线图模型构建[J]. 北京大学学报（医学版）, 2024, 56(5): 896-901.
[2] 刘家骏, 刘国康, 朱玉虎. 免疫相关性重症肺炎1例[J]. 北京大学学报（医学版）, 2024, 56(5): 932-937.
[3] 黄教悌,胡菁,韩博. 治疗相关神经内分泌前列腺癌机制研究与靶向治疗新进展[J]. 北京大学学报（医学版）, 2024, 56(4): 557-561.
[4] 田宇轩,阮明健,刘毅,李德润,吴静云,沈棋,范宇,金杰. 双参数MRI改良PI-RADS评分4分和5分病灶的最大径对临床有意义前列腺癌的预测效果[J]. 北京大学学报（医学版）, 2024, 56(4): 567-574.
[5] 姚凯烽,阮明健,李德润,田宇轩,陈宇珂,范宇,刘毅. 靶向穿刺联合区域系统穿刺对PI-RADS 4~5分患者的前列腺癌诊断效能[J]. 北京大学学报（医学版）, 2024, 56(4): 575-581.
[6] 欧俊永,倪坤明,马潞林,王国良,颜野,杨斌,李庚午,宋昊东,陆敏,叶剑飞,张树栋. 肌层浸润性膀胱癌合并中高危前列腺癌患者的预后因素[J]. 北京大学学报（医学版）, 2024, 56(4): 582-588.
[7] 王滨帅,邱敏,张前进,田茂锋,刘磊,王国良,陆敏,田晓军,张树栋. 6例肾尤文肉瘤伴静脉瘤栓的诊治[J]. 北京大学学报（医学版）, 2024, 56(4): 636-639.
[8] 虞乐,邓绍晖,张帆,颜野,叶剑飞,张树栋. 具有低度恶性潜能的多房囊性肾肿瘤的临床病理特征及预后[J]. 北京大学学报（医学版）, 2024, 56(4): 661-666.
[9] 舒帆,郝一昌,张展奕,邓绍晖,张洪宪,刘磊,王国良,田晓军,赵磊,马潞林,张树栋. 肾部分切除术治疗囊性肾癌的功能学和肿瘤学结果：单中心回顾性研究[J]. 北京大学学报（医学版）, 2024, 56(4): 667-672.
[10] 方杨毅,李强,黄志高,陆敏,洪锴,张树栋. 睾丸鞘膜高分化乳头状间皮肿瘤1例[J]. 北京大学学报（医学版）, 2024, 56(4): 741-744.
[11] 柴晓东,孙子文,李海爽,朱靓怡,刘小旦,刘延涛,裴斐,常青. 髓母细胞瘤分子亚型中CD8+T淋巴细胞浸润的临床病理特点[J]. 北京大学学报（医学版）, 2024, 56(3): 512-518.
[12] 林国中,马长城,吴超,司雨,杨军. 微通道技术在颈椎管肿瘤微创切除术中的应用[J]. 北京大学学报（医学版）, 2024, 56(2): 318-321.
[13] 俞光岩. 儿童唾液腺疾病[J]. 北京大学学报（医学版）, 2024, 56(1): 1-3.
[14] 薛蔚,董樑,钱宏阳,费笑晨. 前列腺癌新辅助治疗与辅助治疗的现状及进展[J]. 北京大学学报（医学版）, 2023, 55(5): 775-780.
[15] 薛子璇,唐世英,邱敏,刘承,田晓军,陆敏,董靖晗,马潞林,张树栋. 青年肾肿瘤伴瘤栓的临床病理特征及预后分析[J]. 北京大学学报（医学版）, 2023, 55(5): 802-811.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
ISSN 1671-167X
CN 11-4691/R
主管单位：中华人民共和国教育部
主办单位：北京大学
地址： 北京市海淀区学院路38号 北京大学医学部 《北京大学学报（医学版）》
邮编：100191
电话：010-82801551
Email： xbbjb2@bjmu.edu.cn

《北京大学学报（医学版）》
微信公众号
版权所有 © 2018 《北京大学学报（医学版）》编辑部